A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

• Status: Completed
• Trial end date: 2008-11-09

Summary

Theobjectiveofthisstudyistoevaluatethecomparativebioavailabilitybetween:

• ErlotinibHCl150mgTablets(Novopharm Limited,Canada)and

• Tarceva® 150mgTablets(Hoffmann-LaRocheLimited,Canada) afterasingle-doseinhealthysubjectsunderfastingconditions.

• Phase: Phase 4

Details

• Lead Sponsor: Quadras Scientific Solutions
• Treatments: Erlotinib Hydrochloride